Search by conditions:

 

Protocol Description Phase
14-035 A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation  (View details on clinicaltrial.gov) Phase I
16-054 Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma and the Longterm Follow-up of Subjects Treated with bb2121  (View details on clinicaltrial.gov) Phase I
15-105 1205-01: A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas  (View details on clinicaltrial.gov) Phase I
15-341 A 3-Arm Phase 2 Double-Blind Randomized Study of Carboplatin, Pemetrexed Plus Placebo versus Carboplatin, Pemetrexed plus 1 or 2 Truncated Courses of Demcizumab in Subjects with Non-Squamous Non-Small Cell Lung Cancer  (View details on clinicaltrial.gov) Phase II
14-367 A Blanket Protocol to Study Oral Regorafenib in Patients with Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-Like Sarcomas  (View details on clinicaltrial.gov) Phase II
16-030 A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158)  (View details on clinicaltrial.gov) Phase II
14-135 A Dose-Finding Phase 1 Study of TAS-120 in Patients with Advanced Solid Tumors with or without Fibroblast Growth Factor/Receptor(FGF/FGFR)- Related Abnormalities Followed by a Phase 2 Study in Patients with Advanced Solid Tumors or Multiple Myeloma FGF/FGFR-Related Abnormalities  (View details on clinicaltrial.gov) Phase II
15-271 A Double-Blind, Randomized, Placebo-Controlled Phase 3 Study of Orally Administered PLX3397 in Patients with Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath  (View details on clinicaltrial.gov) Phase III
14-004 A Four Part, Phase 1, Multi-center, Open-label Study of DKN-01 in Combination with Weekly Paclitaxel; Part A: A Dose-Escalation Study in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors; Part B: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors; Part C: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal or Gastroesophageal Junction Adenocarcinoma; Part D: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal Squamous Cell Cancer  (View details on clinicaltrial.gov) Phase I
14-537 A Multiarm, Open-label, Phase 1b Study of MLN2480 (an Oral A-, B-, and CRAF Inhibitor) in Combination With MLN0128 (an Oral mTORC 1/2 Inhibitor), or Alisertib (an Oral Aurora A Kinase Inhibitor), or Paclitaxel, in Adult Patients With Advanced Nonhematologic Malignancies  (View details on clinicaltrial.gov) Phase I
14-389 A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination with Ascending Doses of Novel Therapeutics in Patients with EGFRm+ Advanced NSCLC who have progressed following therapy with an EGFR TKI (TATTON)  (View details on clinicaltrial.gov) Phase I
15-259 A Multicenter Open-Label Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with MEDI4736, in Subjects with Relapsed or Refractory Lymphomas  (View details on clinicaltrial.gov) Phase II
14-031 A Multicenter Phase 1 Ascending Dose Study of DCC-2701 to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
15-096 A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects With Melanoma Metastatic to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy  (View details on clinicaltrial.gov) Phase II
15-398 A Multicenter Phase II Clinical Trial of Lubrinectedin (PM01183) In Selected Advanced Solid Tumors.  (View details on clinicaltrial.gov) Phase II
14-568 A Multicenter Phase II, Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel With or Without NPC-1C in Patients With Metastatic or Locally Advanced Pancreatic Cancer Previously Treated With FOLFIRINOX  (View details on clinicaltrial.gov) Phase II
15-497 A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors  (View details on clinicaltrial.gov) Phase II
15-140 A Multi-center, Open-label Study to Assess the Safety and Efficacy of Combination Ceritinib (LDK378) and Nivolumab in Adult Patients With Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC)  (View details on clinicaltrial.gov) Phase I
13-412 A Multicenter, Open-label, Phase 1b Study of MLN0128 (an Oral mTORC1/2 Inhibitor) in Combination With MLN1117 (an Oral PI3Kα Inhibitor) in Adult Patients With Advanced Nonhematologic Malignancies  (View details on clinicaltrial.gov) Phase I
14-438 A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
15-421 A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A (Apilimod Dimesylate Capsules) Administered Orally in Subjects with Relapsed or Refractory B-Cell Non-Hodgkins's Lymphoma  (View details on clinicaltrial.gov) Phase I
15-522 A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma  (View details on clinicaltrial.gov) Phase I
15-446 A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and pharmacodynamics of AMG 224 in Subjects with Relapsed or Refractory Multiple Myeloma  (View details on clinicaltrial.gov) Phase I
14-526 A Phase 1 Study of ABBV-221 in Subjects with Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor  (View details on clinicaltrial.gov) Phase I
14-191 A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins, in Patients with Acute Leukemia, Myelodysplastic Syndrome, or Myelodysplastic/Myeloproliferative Neoplasms  (View details on clinicaltrial.gov) Phase I
14-246 A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX7486-TsOH as a Single Agent and in Combination with Gemcitabine and nab-Paclitaxel in Patients with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
16-076 A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BLU-554 in Patients with Hepatocellular Carcinoma and Cholangiocarcinoma  (View details on clinicaltrial.gov) Phase I
12-312 A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults with Ovarian Cancer and other FOLR1-Positive Solid Tumors  (View details on clinicaltrial.gov) Phase I
14-524 A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD007, A Humanized gpA33 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Relapsed/Refractory Metastatic Colorectal Carcinoma  (View details on clinicaltrial.gov) Phase I
15-404 A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)  (View details on clinicaltrial.gov) Phase I
15-401 A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, A Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-881 in Patients with Advanced Hematologic Malignancies with an IDH1 and/or IDH2 Mutation  (View details on clinicaltrial.gov) Phase I
14-045 A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Solid Tumors, Including Glioma, with an IDH1 Mutation  (View details on clinicaltrial.gov) Phase I
13-371 A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation  (View details on clinicaltrial.gov) Phase I
15-527 A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2 Mutation  (View details on clinicaltrial.gov) Phase I
11-217 A Phase 1, Open Label, Dose Escalation Study of MGA271 (Fcoptimized Humanized Anti-B7-H3 Monoclonal Antibody) in Patients with Refractory B7-H3-Expressing Neoplasms or Neoplasms Whose Vasculature Expresses B7-H3  (View details on clinicaltrial.gov) Phase I
15-577 A Phase 1, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KTN0158 in Adult Patients with KIT Positive Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
14-543 A Phase 1, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 Administered Intravenously as a Single Agent to Patients with Locally Advanced or Metastatic Solid Tumors  (View details on clinicaltrial.gov) Phase I
16-008 A Phase 1/1b First-In-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
14-308 A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies  (View details on clinicaltrial.gov) Phase I
15-207 A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination with Nivolumab in Advanced /Metastatic Solid Tumors and B Cell Non-Hodgkins Lymphoma  (View details on clinicaltrial.gov) Phase II
15-471 A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients with Advanced Breast Cancer  (View details on clinicaltrial.gov) Phase I
15-242 A Phase 1/2 Open-Label, Dose Escalation Study of PRTX-100 in Adult Patients with Persistent/Chronic Immune Thrombocytopenia  (View details on clinicaltrial.gov) Phase II
14-195 A Phase 1/2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, A Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS)  (View details on clinicaltrial.gov) Phase II
15-576 A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies  (View details on clinicaltrial.gov) Phase II
13-474 A Phase 1/2 Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors  (View details on clinicaltrial.gov) Phase II
14-177 A Phase 1/2 Study of SL-701, a Subcutaneously Injected Multivalent Glioma Associated Antigen Vaccine, in Adult Patients with Recurrent Glioblastoma  (View details on clinicaltrial.gov) Phase II
16-143 A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer  (View details on clinicaltrial.gov) Phase II
14-271 A Phase 1/2a, Multicenter, Open-Label Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Confirmed to be Positive for TrkA, TrkB, TrkC, ROS1, or ALK Molecular Alterations  (View details on clinicaltrial.gov) Phase I
15-134 A Phase 1a/1b Multicenter, Single-Arm, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Preliminary Activity of Oral ACY-241 Alone and in Combination With Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed or Relapsed-and-Refractory Multiple Myeloma  (View details on clinicaltrial.gov) Phase I
14-189 A Phase 1a/1b Study of the Oral TRK Inhibitor LOXO-101 in Subjects With Adult Solid Tumors  (View details on clinicaltrial.gov) Phase I
14-501 A phase 1b dose-escalation study of SGN-CD33A in combination with standard-of-care for patients with newly diagnosed acute myeloid leukemia (AML)  (View details on clinicaltrial.gov) Phase I
14-554 A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects with Advanced Non-small Cell Lung Cancer  (View details on clinicaltrial.gov) Phase I
16-132 A Phase 1b Study of Safety and Immune Response to PVX-410 Vaccine Alone and in Combination with an Antibody Targeting the PD-1/PD-L1 Pathway in HLA-A2+ Subjects Who Have Completed Initial Standard Treatment of Stage II or III Triple Negative Breast Cancer (TNBC)  (View details on clinicaltrial.gov) Phase I
14-539 A Phase 1b Study of SAR650984 (Anti-CD38 mAb) in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma  (View details on clinicaltrial.gov) Phase I
14-354 A Phase 1b Study of the Safety and Pharmacology of MPDL3280A Administered with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer  (View details on clinicaltrial.gov) Phase I
15-483 A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer  (View details on clinicaltrial.gov) Phase I
15-505 A Phase 1b Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in Combination with Bevacizumab, Carboplatin or Pegylated Liposomal Doxorubicin in Adults with Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, or Endometrial Cancer  (View details on clinicaltrial.gov) Phase I
13-562 A Phase 1b, Open Label, Dose Escalation Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Axitinib (AG-013736) In Combination with Crizotinib (PF-02341066) in Patients with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
16-057 A Phase 1b/2 Open-label, Randomized Study of 2 Combinations Of Isocitrate Dehydrogenase (idh) Mutant Targeted Therapies Plus Azacitidine: Oral Ag-120 Plus Subcutaneous Azacitidine and Oral Ag-221 Plus Sc Azacitidine in Subjects with Newly Diagnosed Acute Myeloid Leukemia Harboring an Idh1 or an Idh2 Mutation, Respectively, Who are Not Candidates to Receive Intensive Induction Chemotherapy  (View details on clinicaltrial.gov) Phase II
14-089 A Phase 1b/2 Study of Ramucirumab in Combination with LY2875358 in Patients with Advanced Cancer  (View details on clinicaltrial.gov) Phase II
15-343 A Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Subjects with Metastatic Castrate-Resistant Prostate Cancer  (View details on clinicaltrial.gov) Phase II
15-523 A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects with Recurrent Glioblastoma Multiforme (GBM)  (View details on clinicaltrial.gov) Phase II
14-332 A Phase 1b/2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 232 Combined with Trametinib and Dabrafenib or Trametinib in Adult Subjects with Metastatic Cutaneous Melanoma  (View details on clinicaltrial.gov) Phase II
15-226 A Phase 1B/Randomized Phase 2 Study to Evaluate LY3039478 in Combination with Dexamethasone in T-ALL/T-LBL Patients  (View details on clinicaltrial.gov) Phase II
14-166 A Phase 2 Clinical Trial of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Microsatellite High (MSI-H) Colon Cancer  (View details on clinicaltrial.gov) Phase II
16-019 A Phase 2 Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor  (View details on clinicaltrial.gov) Phase II
15-295 A Phase 2 Study of MM-121 in Combination with Docetaxel or Pemetrexed versus Docetaxel or Pemetrexed Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer  (View details on clinicaltrial.gov) Phase II
16-700 A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian Cancer  (View details on clinicaltrial.gov) Phase II
14-566 A Phase 2 Study of Pembrolizumab (MK-3475) After Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma and Diffuse Large B Cell Lymphoma  (View details on clinicaltrial.gov) Phase II
16-069 A Phase 2, Multi-Center, Open Label, Simon Two-Stage Study to Evaluate the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia  (View details on clinicaltrial.gov) Phase II
15-571 A Phase 2, Single-Arm Study of Denosumab in Multiple Myeloma Patients with Renal Insufficiency  (View details on clinicaltrial.gov) Phase II
14-059 A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07  (View details on clinicaltrial.gov) Phase III
15-282 A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy  (View details on clinicaltrial.gov) Phase III
13-225 A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide, Bortezomib and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma  (View details on clinicaltrial.gov) Phase III
15-299 A Phase 3B, Prospective, Randomized, Open-Label, Blind Evaluator (Probe) Study Evaluating the Efficacy and Safety of (LMW) Heparin/Edoxaban Versus Dalteparin in Venous Thromboembolism Associated with Cancer  (View details on clinicaltrial.gov) Phase III
12-487 A Phase I Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (BMS-986015) Administered in Combination with Anti-PD-1 (BMS-936558) in Advanced Refractory Solid Tumors  (View details on clinicaltrial.gov) Phase I
12-283 A Phase I Dose-Escalation Study of Cisplatin and Radiation Therapy for Patients With Triple Negative Breast Cancer  (View details on clinicaltrial.gov) Phase I
06-068 A Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066. A CMET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally To Patients With Advanced Cancer  (View details on clinicaltrial.gov) Phase I
10-457 A Phase I Study of Chemoradiation with Midostaurin (PKC412) for Locally Advanced Rectal Cancer  (View details on clinicaltrial.gov) Phase I
13-581 A Phase I Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins, in Patients with Previously Treated Multiple Myeloma  (View details on clinicaltrial.gov) Phase I
13-348 A Phase I Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins, in Patients with Progressive Lymphoma  (View details on clinicaltrial.gov) Phase I
14-580 A Phase I Study of IDH305 in Patients with Advanced Malignancies that Harbor IDH1R132 Mutations  (View details on clinicaltrial.gov) Phase I
14-455 A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 as a Single Agent and in Combination with Standard Chemotherapy in Patients with Advanced and/or Treatment-Refractory Solid Tumors  (View details on clinicaltrial.gov) Phase I
13-240 A Phase I Study with a Personalized NeoAntigen Cancer Vaccine in Melanoma  (View details on clinicaltrial.gov) Phase I
15-023 A Phase I Trial Of Intensity-modulated Radiation Therapy Using A Contralateral Esophagus Sparing Technique In Locally Advanced Non-Small Cell Lung Cancer and Limited-Stage Small Cell Lung Cancer  (View details on clinicaltrial.gov) Phase I
13-251 A Phase I, Gene Alteration-based, Open Label, Multicenter Study of Oral Debio 1347 (CH5183284) in Patients With Advanced Solid Malignancies, Whose Tumours Have an Alteration of the Fibroblast Growth Factor Receptor (FGFR) 1, 2 or 3 Genes  (View details on clinicaltrial.gov) Phase I
15-268 A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-881 in Patients with Advanced Solid Tumors, Including Gliomas, with an IDH1 and/or IDH2 Mutation.  (View details on clinicaltrial.gov) Phase I
15-417 A Phase I, Multicenter, Open-Label, Two-Part, Dose-Escalation Study of RAD1901 in Post-Menopausal Women with Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer  (View details on clinicaltrial.gov) Phase I
11-314 A Phase I, Open Label, Dose Escalation Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously As a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors  (View details on clinicaltrial.gov) Phase I
14-263 A Phase I, Open-Label, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of DMUC4064A Administered Intravenously to Patients with Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer  (View details on clinicaltrial.gov) Phase I
15-074 A Phase I, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel plus or minus Gemcitbine in Pancreatic Cancer, nab-Paclitaxel/Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Metastatic Breast Cancer  (View details on clinicaltrial.gov) Phase I
15-084 A Phase I, Two-Part, Multi-Center, Non-Randomized, Open-Label, Multiple Dose First-in-Human Study of DS-6051b, an Oral ROS1 and NTRK Inhibitor, in Subjects with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
16-139 A Phase I/Ib, Open Label Study of LSZ102 Single Agent and LSZ102 in Combination With Either LEE011 (LSZ102 + LEE011) or BYL719 (LSZ102 + BYL719) in Patients With Advanced or Metastatic ER+ Breast Cancer Who Have Progressed After Endocrine Therapy  (View details on clinicaltrial.gov) Phase I
14-121 A Phase I/II Clinical Trial to Study the Safety and Tolerability of MK-3475 + Pegylated Interferon alfa-2b (PEG-IFN) and MK-3475 + Ipilimumab (IPI) in Subjects With Advanced Melanoma (MEL) and Renal Cell Carcinoma (RCC)  (View details on clinicaltrial.gov) Phase II
13-541 A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers  (View details on clinicaltrial.gov) Phase II
15-542 A Phase I/II Trial of Increased Dose Intensity Modulated Proton Therapy (IMPT) for High-Grade Meningiomas  (View details on clinicaltrial.gov) Phase II
15-055 A Phase I/II Trial to Evaluate the Safety and Tolerability of Alectinib and Bevacizumab in Patients with Advanced, ALK-Positive, Non-Small Cell Lung Cancer  (View details on clinicaltrial.gov) Phase II
14-249 A Phase I/II, Multicenter, Open-Label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients with EGFRmut Solid Malignancies  (View details on clinicaltrial.gov) Phase II
14-464 A Phase I/II, Multicenter, Open-label Study of FGF401 in Adult Patients With Hepatocellular Carcinoma or Solid Malignancies Characterized by Positive FGFR4 and KLB Expression  (View details on clinicaltrial.gov) Phase II
13-123 A Phase Ib Open-label, Dose-escalation Study of the Safety and Pharmacology of GDC-0032 in Combination With Either Docetaxel or Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer  (View details on clinicaltrial.gov) Phase I
15-283 A Phase IB Study of Ibrutinib in Combination with Obinutuzumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia  (View details on clinicaltrial.gov) Phase I
12-252 A Phase Ib Study of the Safety and Pharmacology of MPDL3280A Administered With Bevacizumab and/or With Chemotherapy in Patients With Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
14-301 A Phase IB Study of the Safety and Pharmacology of MPDL3280A Administered with Cobimetinib in Patients with Locally Advanced or Metastatic Solid Tumors  (View details on clinicaltrial.gov) Phase I
13-157 A Phase Ib Trial of BYL719 (an α-Specific PI3K Inhibitor) in Combination With Endocrine Therapy in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer  (View details on clinicaltrial.gov) Phase I
12-376 A Phase Ib, Open-Label Study of The Safety and Pharmacology of MPDL3280A Administered in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma  (View details on clinicaltrial.gov) Phase I
15-346 A Phase Ib/II Clinical Study of BBI608 Administered in Combination with Immune Checkpoint Inhibitors to Adult Patients with Advanced Cancers  (View details on clinicaltrial.gov) Phase II
13-313 A Phase Ib/II Clinical Study of BBI608 Administered with Paclitaxel in Adult Patients with Advanced Malignancies  (View details on clinicaltrial.gov) Phase II
15-218 A PHASE Ib/II STUDY OF CRLX101 IN COMBINATION WITH WEEKLY PACLITAXEL IN PATIENTS WITH RECURRENT OR PERSISTENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER  (View details on clinicaltrial.gov) Phase I
13-283 A Phase Ib/II Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive, Her2- Locally Advanced or Metastatic Breast Cancer  (View details on clinicaltrial.gov) Phase II
13-367 A Phase Ib/II, Multicenter Study of the Combination of LEE011 and BYL719 With Letrozole in Adult Patients With Advanced ER+ Breast Cancer  (View details on clinicaltrial.gov) Phase II
15-233 A phase Ib/II, multicenter, open-label study of EGF816 in combination with INC280 in adult patients with EGFR mutated non-small cell lung cancer  (View details on clinicaltrial.gov) Phase I
15-454 A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors  (View details on clinicaltrial.gov) Phase II
15-240 A Phase II Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy for Metastatic Triple-Negative Breast Cancer (mTNBC)  (View details on clinicaltrial.gov) Phase II
15-448 A phase II evaluation of Afatinib, an irreversible human epidermal growth factor receptor 2 (Her2/neu) tyrosine kinase inhibitor, in patients with persistent or recurrent HER2-positive uterine serous carcinoma  (View details on clinicaltrial.gov) Phase II
15-083 A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination with Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas  (View details on clinicaltrial.gov) Phase II
14-311 A Phase II Randomized, Double-Blind Study of Neoadjuvant Letrozole Plus GDC-0032 Versus Letrozole Plus Placebo in Postmenopausal Women with ER-Positive/Her2-Negative, Early Stage Breast Cancer  (View details on clinicaltrial.gov) Phase II
15-118 A Phase II Randomized, Double-blind, Study of Ipatasertib (GDC 0068), An Inhibitor to AKT, in Combination with Paclitaxel as Neoadjuvant Treatment for Patients With Early Stage Triple Negative Breast Cancer  (View details on clinicaltrial.gov) Phase II
16-118 A phase II study of blinatumomab for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma  (View details on clinicaltrial.gov) Phase II
14-219 A Phase II Study of Cabozantinib (XL184) for Plexiform Neurofibromas in Subjects with Neurofibromatosis Type 1 age 16 years or greater  (View details on clinicaltrial.gov) Phase II
15-475 A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma  (View details on clinicaltrial.gov) Phase II
13-220 A Phase II Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung  (View details on clinicaltrial.gov) Phase II
10-308 A Phase II Study Of Proton Beam Therapy For Locally Advanced Sinonasal Malignancies  (View details on clinicaltrial.gov) Phase II
10-206 A Phase II Study of Proton Radiotherapy for Pediatric Brain Tumors requiring Partial Brain Irradiation: An Assessment of Long-term Neurocognitive, Neuroendocrine and Ototoxicity Outcomes  (View details on clinicaltrial.gov) Phase II
11-085 A Phase II Study of Reduced Intensity, Double Umbilical Cord Blood Transplantation Using Fludarabine, Melphalan, and Low Dose Total Body Radiation  (View details on clinicaltrial.gov) Phase II
15-334 A Phase II Study of the Aurora A Kinase Inhibitor Alisertib in Combination With 7+3 Induction Chemotherapy in Patients With High-risk Acute Myeloid Leukemia  (View details on clinicaltrial.gov) Phase II
14-508 A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Combination Therapy for patients with Newly Diagnosed Multiple Myeloma  (View details on clinicaltrial.gov) Phase II
11-208 A Phase II Trial of Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer With Involvement of Bone  (View details on clinicaltrial.gov) Phase II
11-344 A Phase II Trial of HKI-272 (Neratinib) for Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Brain Metastases  (View details on clinicaltrial.gov) Phase II
14-370 A Phase II Trial of Integrating Stereotactic Body Radiation Therapy with Selective Targeted Therapy in Stage IV Oncogene-driven Non-Small Cell Lung Cancer  (View details on clinicaltrial.gov) Phase II
04-188 A Phase II Trial of Proton Radiation for the Treatment of Pediatric Rhabdomyosarcoma  (View details on clinicaltrial.gov) Phase II
13-086 A Phase II Trial of Sunitinib in Never-smokers With Lung Adenocarcinoma: Identification of Oncogenic Alterations Underlying Sunitinib Sensitivity  (View details on clinicaltrial.gov) Phase II
15-512 A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma  (View details on clinicaltrial.gov) Phase II
15-387 A Phase II, Multicenter, Four-cohort Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Received One or Two Prior Lines of Systemic Therapy for Advanced/Metastatic Disease  (View details on clinicaltrial.gov) Phase II
16-007 A Phase II, Open-Label, Single-Arm, Multicenter Study to Evaluate Efficacy and Safety of Pembrolizumab Monotherapy in Subjects with Advanced Recurrent Ovarian Cancer (KEYNOTE-100)  (View details on clinicaltrial.gov) Phase II
14-126 A Phase II, Open-label, Study in Subjects with BRAF V600E Mutated Rare Cancers with Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib.  (View details on clinicaltrial.gov) Phase II
16-707 A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation  (View details on clinicaltrial.gov) Phase III
15-415 A Phase III Double-Blind, Randomized, Parallel Group, Multicenter Placebo-Controlled Trial to Study the Efficacy and Safety of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura  (View details on clinicaltrial.gov) Phase III
16-703 A Phase III Randomized Trial Comparing Physician/Patient Choice of High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma  (View details on clinicaltrial.gov) Phase III
14-565 A Phase III Randomized, Double-blind, Placebo-controlled Study of LEE011 or Placebo in Combination With Tamoxifen and Goserelin or a Non-steroidal Aromatase Inhibitor (NSAI) and Goserelin for the Treatment of Premenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer (MONALEESA-7)  (View details on clinicaltrial.gov) Phase III
15-111 A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to assess the efficacy and safety of Olaparib Monotherapy versus Physician’s Choice Single Agent Chemotherapy in the Treatment of Platinum Sensitive Relapsed Ovarian Cancer in Patients Carrying Germline BRCA1/2 Mutations  (View details on clinicaltrial.gov) Phase III
15-232 A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advance Renal Cell Carcinoma [IMmotion151]  (View details on clinicaltrial.gov) Phase III
15-191 A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy  (View details on clinicaltrial.gov) Phase III
14-185 A Phase III, Randomized, Open-Label, Multi-Center, Safety and Efficacy Study to Evaluate Nab-Paclitaxel (Abraxane) as Maintenance Treatment After Induction with Nab-Paclitaxel Plus Carboplatin in Subjects with Squamous Cell Non-Small Cell Lung Cancer (NSCLC)  (View details on clinicaltrial.gov) Phase III
13-075 A Pilot Feasibility Study of Definitive Concurrent Chemoradiation with Pencil Beam Scanning Proton Beam in Combination with 5-Fluorouracil and Mitomycin-C for Carcinoma of the Anal Canal  (View details on clinicaltrial.gov) N/A
16-023 A Pilot Study to determine the feasibility of Fecal Material Transplantation (FMT) in Hematopoietic Stem Cell Transplantation (HSCT) recipients  (View details on clinicaltrial.gov) N/A
14-421 A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated with Chemoradiation or Immunotherapy  (View details on clinicaltrial.gov) N/A
15-468 A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician's Choice for Metastatic Triple Negative Breast Cancer (mTNBC)  (View details on clinicaltrial.gov) Phase III
13-021 A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma  (View details on clinicaltrial.gov) Phase II
13-170 A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone (Including a Lead-In Phase 1B Dose-Escalation Portion) in Patients with Advanced or Metastatic Renal Cell Carcinoma  (View details on clinicaltrial.gov) Phase I
13-048 A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs Paclitaxel in Combination with Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)  (View details on clinicaltrial.gov) Phase II
12-258 A Randomized Phase II Trial of Neoadjuvant Cisplatin vs Doxorubicin/Cyclophosphamide (AC) in Women with Newly Diagnosed Breast Cancer and Germline BRCA Mutations  (View details on clinicaltrial.gov) Phase II
13-630 A Randomized Phase IIB Open Label Study of Nivolumab or Nivolumab in Combination with Ipilimumab versus Bevacizumab in Adult Subjects with Recurrent Glioblastoma (GBM)  (View details on clinicaltrial.gov) Phase II
15-304 A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Capecitabine and Cisplatin With or Without Ramucirumab as First-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (RAINFALL)  (View details on clinicaltrial.gov) Phase III
15-438 A Randomized, Multicenter, Double-Blinded Phase 2 study of Palbociclib plus Cetuximab versus Cetuximab for the Treatment of Human Papillomavirus-Negative, Cetuximab-Naive Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck After Failure of One Prior Platinum-Containing Chemotherapy Regimen  (View details on clinicaltrial.gov) Phase II
15-030 A Randomized, Multi-center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease  (View details on clinicaltrial.gov) Phase III
15-580 A Randomized, Open-Label, Phase 2 Trial of CMB305 (Sequentially Administered LV305 and G305) and Atezolizumab in Patients with Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY-ESO-1  (View details on clinicaltrial.gov) Phase II
10-106 A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age (IFM/DFCI 2009)  (View details on clinicaltrial.gov) Phase III
15-590 A single arm phase 2 study of the dual mTORC1/mTORC2 inhibitor AZD2014 provided on an intermittent schedule for neurofibromatosis 2 patients with progressive or symptomatic meningiomas  (View details on clinicaltrial.gov) Phase II
14-375 A Single-arm Open Label Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer  (View details on clinicaltrial.gov) Phase II
13-521 A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting  (View details on clinicaltrial.gov) Phase III
13-322 A Study to Evaluate Vascular Normalization in Patients with Recurrent Glioblastoma Treated with Bevacizumab using [11C]Temozolomide PET and Vascular MRI  (View details on clinicaltrial.gov) N/A
13-482 A Study to Evaluate Vascular Normalization in Patients with Recurrent Glioblastoma Treated with Bevacizumab using FMISO PET and Vascular MRI  (View details on clinicaltrial.gov) N/A
13-533 A071101: A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, Alliance IND #15380) Vaccine Given with Bevacizumab Versus Bevacizumab alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)  (View details on clinicaltrial.gov) Phase II
15-701 A081105: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)  (View details on clinicaltrial.gov) Phase III
15-700 A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)  (View details on clinicaltrial.gov) N/A
13-311 ABTC-1202:Phase I Study of MK-1775 with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma and Evaluation of Intratumoral Drug Distribution in Patients with Recurrent Glioblastoma  (View details on clinicaltrial.gov) Phase I
14-233 Adcetris (Brentuximab Vedotin) Substitution Vincristine in the OEPA/COPDAC Regimen [Treatment Group 3 (TG3 of Euro-Net C1] with Involved Node Radiation Therapy for High Risk Pediatric Hodgkin Lymphoma (HL)  (View details on clinicaltrial.gov) Phase II
11-464 Afatinib Sequenced with Concurrent Chemotherapy and Radiation in EGFR-Mutant Non-Small Cell Lung Tumors: The ASCENT Trial.  (View details on clinicaltrial.gov) Phase II
13-505 An Open Label, Two-Part, Phase Ib/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor Trametinib and the BCL2-Family Inhibitor Navitoclax (ABT-263) in Combination in Subjects With KRAS Mutation-Positive Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
15-403 An Open-Label Multicenter Phase 1 Study of E7046 in Subjects With Selected Advanced Malignancies  (View details on clinicaltrial.gov) Phase I
16-022 An Open-Label, Dose-Finding Study of Vedolizumab IV Plus Standard of Care for Graft-Versus-Host Disease (GvHD) Prophylaxis in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)  (View details on clinicaltrial.gov) Phase I
15-212 An Open-Label, Multi-Center Phase 1 Study to Investigate the Safety and Tolerability of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients With CD20+ B-Cell Malignancies Previously Treated With CD20-Directed Antibody Therapy  (View details on clinicaltrial.gov) Phase I
15-435 An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements (STARTRK-2)  (View details on clinicaltrial.gov) Phase II
14-314 An Open-Label, Phase 1 Dose Escalation Study of Oral ASP8273 in Subjects with Non-Small-Cell Lung Cancer (NSCLC) who have Epidermal Growth Factor Receptor (EGFR) Mutations  (View details on clinicaltrial.gov) Phase I
13-615 An Open-Label, Phase 2 Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification  (View details on clinicaltrial.gov) Phase II
14-569 An Open-Label, Phase I Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer  (View details on clinicaltrial.gov) Phase I
11-010 An Open-Label, Phase I/II, Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer  (View details on clinicaltrial.gov) Phase I
13-043 An Open-Label, Phase I/IIA Study of GDC-0810 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer  (View details on clinicaltrial.gov) Phase I
15-530 An Open-label, Phase Ib/II Clinical Trial of CDK 4/6 Inhibitor, Ribociclib (LEE011), in Combination with Trastuzumab or TDM-1 for Advanced/Metastatic HER2-Positive Breast Cancer  (View details on clinicaltrial.gov) Phase II
16-108 An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as first line-therapy in stage IV Non-Small Cell Lung Cancer (NSCLC)  (View details on clinicaltrial.gov) Phase II
15-544 An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects with Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)  (View details on clinicaltrial.gov) Phase II
12-188 BMT CTN 1101: A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow (haplo-BM) for Patients with Hematologic Malignancies  (View details on clinicaltrial.gov) Phase III
13-453 BMT CTN 1102: A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic Syndrome  (View details on clinicaltrial.gov) Phase III
12-134 CALGB 30610: Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide  (View details on clinicaltrial.gov) Phase III
10-327 CALGB 50801: Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)  (View details on clinicaltrial.gov) Phase II
12-440 CALGB 51101: A Randomized Phase II Trial of Myeloablative Versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell Lymphoma  (View details on clinicaltrial.gov) Phase II
14-096 Carfilzomib plus Belinostat in Relapsed/Refractory Non-Hodgkin Lymphoma Subtypes: A Phase I Study  (View details on clinicaltrial.gov) Phase I
08-207 Circulating Tumor Cell Analysis in Patients with Localized Prostate Cancer Undergoing Prostatectomy  (View details on clinicaltrial.gov) N/A
13-492 Clinical and Biological Predicators of Chemotherapy Toxicity in Older Adults  (View details on clinicaltrial.gov) N/A
15-032 COG AALL1232: A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)  (View details on clinicaltrial.gov) Phase III
07-125 COG ACNS0332: A Phase III Study Investigating the Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients  (View details on clinicaltrial.gov) Phase III
09-379 COG AHEP0731: Treatment of Children with All Stages of Hepatoblastoma  (View details on clinicaltrial.gov) Phase III
14-110 COG ANHL12P1: A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL) IND # 117117  (View details on clinicaltrial.gov) Phase II
10-239 COG-ACNS0831: Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 Years  (View details on clinicaltrial.gov) Phase III
14-037 Dose reduction of preoperative radiotherapy in myxoid liposarcoma  (View details on clinicaltrial.gov) Phase II
15-709 E1910: A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults  (View details on clinicaltrial.gov) Phase III
15-702 E4512: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein  (View details on clinicaltrial.gov) Phase III
13-465 ECOG 3612: A Randomized Phase II Trial of Ipilimumab with or without Bevacizumab in Patients with Unresectable Stage III or Stage IV Melanoma  (View details on clinicaltrial.gov) Phase II
12-307 Evaluation of PET/MRI in Children with Cancer  (View details on clinicaltrial.gov) N/A
14-520 Exploration of Activity of RAD001 in Vestibular Schwannomas and Meningiomas: An NF2 Therapeutic Development Consortium Trial  (View details on clinicaltrial.gov) N/A
16-195 Femara (Letrozole) Plus Ribociclib (LEE011) or Placebo as Neo-adjuvant Endocrine Therapy for Women with ER-positive, HER2-negative Early Breast Cancer  (View details on clinicaltrial.gov) Phase II
12-452 GOG-0279:Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC#613327) Concurrent with Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva  (View details on clinicaltrial.gov) Phase II
10-218 Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma  (View details on clinicaltrial.gov) Phase II
09-273 HOD08: Reduced Duration Stanford V Chemotherapy with Low-Dose Tailored-Field Radiation Therapy for Favorable Risk Pediatric Hodgkin Lymphoma  (View details on clinicaltrial.gov) Phase II
13-209 Investigator-Initiated, Pilot Translational Study of Circulating Tumor Cells to Identify Predictive Factors of Response to Abiraterone Acetate in Men with Castration-Resistant Prostate Cancer.  (View details on clinicaltrial.gov) N/A
14-056 Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer  (View details on clinicaltrial.gov) Phase II
12-023 NCCTG-N1048: A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision  (View details on clinicaltrial.gov) Phase III
14-242 Non-Comparative, Two-Cohort, Single Arm, Open-label, Phase 2 Study of Nivolumab (BMS-936558) in Classical Hodgkin Lymphoma (cHL) Subjects after Failure of Autologous Stem Cell Transplant (ASCT)  (View details on clinicaltrial.gov) Phase II
15-423 Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 1/2 Study of Nivolumab (BMS- 936558) in Subjects with Virus-Positive and Virus-Negative Solid Tumors  (View details on clinicaltrial.gov) Phase II
13-195 Non-steroidal Anti-inflammatory Drugs (Meloxicam) to Mobilize Hematopoietic Stem Cells: A Phase II Randomized Trial  (View details on clinicaltrial.gov) Phase II
15-708 NRG-BN001: Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma  (View details on clinicaltrial.gov) Phase II
15-711 NRG-GU001: Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/pT4 Urothelial Bladder Cancer  (View details on clinicaltrial.gov) Phase II
15-157 Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies  (View details on clinicaltrial.gov) Phase II
14-482 Open Label, Adaptive Design, Ascending, Multiple-Dose Study to Evaluate Safety and Efficacy of BMS-986004 (Anti-CD40L dAb) in Adult Subjects with Primary Immune Thrombocytopenia(ITP)  (View details on clinicaltrial.gov) Phase II
15-306 Open-Label, Multicenter, Dose Escalation Phase IB Study with Expansion Phase to Evaluate the Safety, Pharmacokinetics and Activiity of RO5509554 and MPDL3280A Administered in Combination in Patients with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
12-466 Open-label, Phase 2 Study of Bevacizumab in Children with Neurofibromatosis 2 and Progressive Vestibular Schwannomas that are Poor Candidates for Standard Treatment with Surgery or Radiation  (View details on clinicaltrial.gov) Phase II
15-488 PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer  (View details on clinicaltrial.gov) Phase III
11-318 Phase 1, Multicenter, Open-label, Dose-escalation Study of ACE-011 in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma  (View details on clinicaltrial.gov) Phase I
13-408 Phase 1/2 Study of PF-06463922 (an ALK/ROS1 Tyrosine Kinase Inhibitor) In Patients With Advanced Non-Small Cell Lung Cancer Harboring Specific Molecular Alterations  (View details on clinicaltrial.gov) Phase II
16-210 Phase 1b Study to Assess The Safety, Tolerability, And Clinical Activity of Gedatolisib In Combination With Palbociclib and Either Letrozole or Fulvestrant in Women with Metastatic or Locally Advanced/Recurrent Breast Cancer (MBC)  (View details on clinicaltrial.gov) Phase I
16-178 Phase 1b/2 Study of PF-04136309 in Combination with Gemcitabine and Nab-paclitaxel in Patients with Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma  (View details on clinicaltrial.gov) Phase II
15-018 Phase 1b/2, Multicenter, Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose and Recommended Phase 2 Dose of DCR-MYC, a Lipid Nanoparticle (LNP)- Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients with Hepatocellular Carcinoma (HCC)  (View details on clinicaltrial.gov) Phase II
15-479 Phase 1b/2, Open-label, Dose-finding Study to Evaluate Safety, Efficacy, Pharmacokinetics and Pharmacodynamics Of Avelumab (msb0010718c) in Combination with Either Crizotinib or Pf-06463922 in Patients with Advanced or Metastatic Non-small Cell Lung Cancer  (View details on clinicaltrial.gov) Phase I
14-412 Phase 2 study to Evaluate the Clinical Efficacy and Safety of MEDI4736 in Patients with Glioblastoma (GBM)  (View details on clinicaltrial.gov) Phase II
13-613 Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma  (View details on clinicaltrial.gov) Phase I
14-213 Phase I Dose Escalation Study of Velcade in Combination with Lenalidomide in Patients with Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) After Allogeneic Stem Cell Transplantation  (View details on clinicaltrial.gov) Phase I
15-142 Phase I Dose Escalation Study to Investigate the Safety, Immunoregulatory Activity, Pharmacokinetics, and Preliminary Antitumor Activity of Anti-Programmed-Death-1 (PD-1) Antibody (BMS-936558) in Advanced Hepatocellular Carcinoma in Subjects with or without Chronic Viral Hepatitis  (View details on clinicaltrial.gov) Phase I
13-010 Phase I Dose-Escalation, Safety, Pharmacokinetics and Pharmacodynamic Study of BVD-523 in Patients with Advanced Malignancies  (View details on clinicaltrial.gov) Phase I
12-267 Phase I Study of Afatinib with Postoperative Radiation Therapy for Intermediate and High Risk Squamous Cancer of the Head and Neck (SCCHN)  (View details on clinicaltrial.gov) Phase I
14-186 Phase I Study of AT13387 in Combination With Dabrafenib and Trametinib in BRAF-Inhibitor Resistant Patients With BRAF-Mutant Melanoma and Other Solid Tumors  (View details on clinicaltrial.gov) Phase I
14-200 Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults  (View details on clinicaltrial.gov) Phase I
13-115 Phase I Study of Olaparib and Temozolomide in Adult Patients with Recurrent/Metastatic Ewing's Sarcoma following failure of prior chemotherapy  (View details on clinicaltrial.gov) Phase I
12-159 Phase I Study of the Oral PI3kinase Inhibitor BKM120 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or Recurrent High Grade Serous Ovarian Cancer  (View details on clinicaltrial.gov) Phase I
13-239 Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD)  (View details on clinicaltrial.gov) Phase I
13-040 Phase I Trial of Brentuximab Vedotin With Re-induction Chemotherapy in Patients With Relapsed, CD30 Expressing, Acute Myeloid Leukemia (AML)  (View details on clinicaltrial.gov) Phase I
13-363 Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)  (View details on clinicaltrial.gov) Phase I
16-004 Phase I, Multicenter, Open-Label, Clinical and Pharmacokinetics Study of PM01183 in Combination with Irinotecan in Pretreated Patients with Selected Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
13-424 Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma and Other Solid Tumors  (View details on clinicaltrial.gov) Phase II
15-121 Phase I/II Study of Olaparib and Temozolomide in Patients with Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy  (View details on clinicaltrial.gov) Phase II
12-100 Phase I/II Trial of Pre-Operative Image Guided Intensity Modulated Proton Radiation Therapy (IMPT) with Simultaneously Integrated Boost to the High Risk Margin for Retroperitoneal Sarcomas  (View details on clinicaltrial.gov) Phase II
13-598 Phase I: LDE225 for Steroid-Refractory GVHD  (View details on clinicaltrial.gov) Phase I
15-024 Phase Ib dose-escalation trial of Taselisib (GDC-0032) in combination with anti-HER2 therapies in participants with advanced HER2+ Breast Cancer  (View details on clinicaltrial.gov) Phase I
14-056-RISK Phase II Double-Blind Randomized Controlled Trial of Naltrexone for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer  (View details on clinicaltrial.gov) Phase II
15-407 Phase II Randomized Trial of Continuation of Post-Transplant Maintenance with Single-Agent Lenalidomide vs. Consolidation/Maintenance with Ixazomib-Lenalidomide-Dexamethasone in Patients with Residual Myeloma  (View details on clinicaltrial.gov) Phase II
12-484 Phase II Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR  (View details on clinicaltrial.gov) Phase II
15-196 Phase II Study of Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma  (View details on clinicaltrial.gov) Phase II
10-116 Phase II Study of Dose-Adjusted EPOCH-Rituxan in Adults with Untreated Burkitt Lymphoma and c-MYC Positive Diffuse Large B-Cell Lymphoma  (View details on clinicaltrial.gov) Phase II
15-359 Phase II Study of Ibrutinib in Patients with Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing.  (View details on clinicaltrial.gov) Phase II
14-218 Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable and Borderline Resectable Pancreatic Cancer  (View details on clinicaltrial.gov) Phase II
09-263 Phase II Study of Proton Radiation Therapy for CNS Germ Cell Tumors; Evaluation of Acute and Late Side Effects  (View details on clinicaltrial.gov) Phase II
10-439 Phase II Study of Proton Radiation Therapy for Low Grade Gliomas  (View details on clinicaltrial.gov) Phase II
13-443 Phase II Study of Proton Radiation Therapy for Neuroblastoma  (View details on clinicaltrial.gov) Phase II
12-456 Phase II Study of Ziv-aflibercept in Patients With Advanced, Progressive Carcinoid Tumors  (View details on clinicaltrial.gov) Phase II
13-249 Phase II Trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults  (View details on clinicaltrial.gov) Phase II
14-338 Phase II Trial of Combination of Elotuzumab and Lenalidomide +/- Dexamethasone in High-Risk Smoldering Multiple Myeloma  (View details on clinicaltrial.gov) Phase II
15-007 Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma  (View details on clinicaltrial.gov) Phase II
14-140 Phase II Trial of Natalizumab (Tysabri) plus Prednisone for Initial Therapy of Acute Graft Versus Host Disease (aGVHD) of the Gastrointestinal Tract  (View details on clinicaltrial.gov) Phase II
16-153 Phase II Trial of Pembrolizumab in Central Nervous System Metastases from Multiple Histologies  (View details on clinicaltrial.gov) Phase II
15-163 Phase II Trial of Ponatinib in Patients with Bevacizumab-Refractory Glioblastoma  (View details on clinicaltrial.gov) Phase II
15-715 Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations  (View details on clinicaltrial.gov) Phase II
12-218 Phase II Trial of Sorafenib in Combination with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma  (View details on clinicaltrial.gov) Phase II
11-497 Phase III Randomized Clinical Trial of Proton Therapy vs IMRT for Low or Low-intermediate Risk Prostate Cancer  (View details on clinicaltrial.gov) Phase III
10-269 Pilot Study of Adjuvant Proton Beam Teletherapy for Post-Hysterectomy Cancers of the Uterus and Cervix with Metastases to Regional Lymph Nodes  (View details on clinicaltrial.gov) N/A
14-333 Pilot Study of EGFR Inhibition with Erlotinib in Cirrhosis to Inhibit Fibrogenesis and Prevent Hepatocellular Carcinoma  (View details on clinicaltrial.gov) N/A
10-205 Pilot Study of Proton Radiation Therapy for Invasive Carcinoma of the Left Breast Following Mastectomy  (View details on clinicaltrial.gov) N/A
16-188 Pragmatic Phase III Randomized Trial of Proton Vs. Photon Therapy for Patients with Non-metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial  (View details on clinicaltrial.gov) Phase III
15-525 Prospective, phase II/III, randomized clinical study to compare BEGEDINA® versus “conventional treatment” for treating steroid resistant acute graft-versus host disease  (View details on clinicaltrial.gov) Phase III
09-361 Proton beam Radiotherapy for Medulloblastoma and Pineoblastoma: An Assessment of Acute Toxicity and Long-term Neurocognitive, Neuroendocrine and Ototoxicity Outcomes  (View details on clinicaltrial.gov) Phase II
12-504 Randomized Phase II Study Comparing Concise Versus Prolonged Afatinib as Adjuvant Therapy for Patients With Resected Stage I-III NSCLC With EGFR Mutation  (View details on clinicaltrial.gov) Phase II
15-185 Randomized Phase II Study Comparing Selumetinib to Placebo for Enhancing the Clinical Efficacy of Radioactive Iodine (RAI) for RAI-Avid Recurrent/Metastatic Thyroid Cancers Uptake  (View details on clinicaltrial.gov) Phase II
15-706 Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma  (View details on clinicaltrial.gov) Phase II
15-724 Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma  (View details on clinicaltrial.gov) Phase III
11-436 Randomized, Double-Blind, Phase II Trial of Vitamin D Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer  (View details on clinicaltrial.gov) Phase II
15-287 Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib  (View details on clinicaltrial.gov) Phase III
10-040 RTOG 0926: A Phase II Protocol for Patients with Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent with Cisplatin Chemotherapy Following a Thorough Transurethral Surgical Restaging  (View details on clinicaltrial.gov) Phase II
13-295 RTOG 1112: Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma  (View details on clinicaltrial.gov) Phase III
14-268 RTOG 1308: Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC  (View details on clinicaltrial.gov) Phase III
14-265 Safety and Feasibility of Lenalidomide in Combination with HLA-mismatched Stem-Cell Microtranplantation as Post-Remission Therapy in Patients with High-Risk Acute Myeloid Leukemia (AML).  (View details on clinicaltrial.gov) Phase I
15-332 SOLAR-1: A phase III randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment  (View details on clinicaltrial.gov) Phase III
15-469 Study of Anti-PD-1 Therapy for HPV-associated Recurrent Respiratory Papilloma Patients with Laryngeal, Tracheal and/or Pulmonary Involvement  (View details on clinicaltrial.gov) Phase II
14-416 SWOG 1400: Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer (LUNG-MAP)  (View details on clinicaltrial.gov) Phase III
14-409 The Impact of HER2 Heterogeneity on the Treatment of Early-Stage HER2-Positive Breast Cancer: A Phase II Study of T-DM1 in Combination with Pertuzumab in the Preoperative Setting  (View details on clinicaltrial.gov) Phase II
282 clinical trials listed

Back to Top